Unravelling the mosaic: Epigenetic diversity in glioblastoma.
brain tumours
cell‐of‐origin
epigenetics
glioblastoma
interpatient heterogeneity
Journal
Molecular oncology
ISSN: 1878-0261
Titre abrégé: Mol Oncol
Pays: United States
ID NLM: 101308230
Informations de publication
Date de publication:
15 Aug 2024
15 Aug 2024
Historique:
revised:
21
06
2024
received:
28
11
2023
accepted:
23
07
2024
medline:
16
8
2024
pubmed:
16
8
2024
entrez:
16
8
2024
Statut:
aheadofprint
Résumé
Glioblastoma is the most common primary malignant brain tumour. Despite decades of intensive research in the disease, its prognosis remains poor, with an average survival of only 14 months after diagnosis. The remarkable level of intra- and interpatient heterogeneity is certainly contributing to the lack of progress in tackling this tumour. Epigenetic dysregulation plays an important role in glioblastoma biology and significantly contributes to intratumour heterogeneity. However, it is becoming increasingly clear that it also contributes to intertumour heterogeneity, which historically had mainly been linked to diverse genetic events occurring in different patients. In this review, we explore how DNA methylation, chromatin remodelling, microRNA (miRNA) dysregulation, and long noncoding RNA (lncRNA) alterations contribute to intertumour heterogeneity in glioblastoma, including its implications for advanced tumour stratification, which is the essential first step for developing more effective patient-specific therapeutic approaches.
Identifiants
pubmed: 39148319
doi: 10.1002/1878-0261.13706
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Brain Tumour Research
Organisme : Barts Charity
ID : MGU0447
Organisme : Cancer Research UK
ID : C23985/A29199
Pays : United Kingdom
Informations de copyright
© 2024 The Author(s). Molecular Oncology published by John Wiley & Sons Ltd on behalf of Federation of European Biochemical Societies.
Références
Dubrow R, Darefsky AS. Demographic variation in incidence of adult glioma by subtype, United States, 1992–2007. BMC Cancer. 2011;11:325.
Mowforth OD, Brannigan J, El Khoury M, Sarathi CIP, Bestwick H, Bhatti F, et al. Personalised therapeutic approaches to glioblastoma: a systematic review. Front Med. 2023;10:1166104.
Lara‐Velazquez M, al‐Kharboosh R, Jeanneret S, Vazquez‐Ramos C, Mahato D, Tavanaiepour D, et al. Advances in brain tumor surgery for glioblastoma in adults. Brain Sci. 2017;7(12):166.
Daneman R, Prat A. The blood‐brain barrier. Cold Spring Harb Perspect Biol. 2015;7(1):a020412.
Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella‐Branger D, et al. The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro Oncol. 2021;23(8):1231–1251.
Brennan CW, Verhaak RGW, McKenna A, Campos B, Noushmehr H, Salama SR, et al. The somatic genomic landscape of glioblastoma. Cell. 2013;155(2):462–477.
Touat M, Li YY, Boynton AN, Spurr LF, Iorgulescu JB, Bohrson CL, et al. Mechanisms and therapeutic implications of hypermutation in gliomas. Nature. 2020;580(7804):517–523.
Hall AW, Battenhouse AM, Shivram H, Morris AR, Cowperthwaite MC, Shpak M, et al. Bivalent chromatin domains in glioblastoma reveal a subtype‐specific signature of glioma stem cells. Cancer Res. 2018;78(10):2463–2474.
Yabo YA, Niclou SP, Golebiewska A. Cancer cell heterogeneity and plasticity: a paradigm shift in glioblastoma. Neuro Oncol. 2022;24(5):669–682.
Christoph S, Alicia S, Fritz T, Vanessa T, Ralf K, Jin KY, et al. The intratumoral heterogeneity in glioblastoma — a limitation for prognostic value of epigenetic markers? Acta Neurochir. 2023;165(6):1635–1644.
Chaligne R, Gaiti F, Silverbush D, Schiffman JS, Weisman HR, Kluegel L, et al. Epigenetic encoding, heritability and plasticity of glioma transcriptional cell states. Nat Genet. 2021;53(10):1469–1479.
Carén H, Pollard SM, Beck S. The good, the bad and the ugly: epigenetic mechanisms in glioblastoma. Mol Aspects Med. 2013;34(4):849–862.
Rasras S, Zibara K, Vosughi T, Zayeri ZD. Genetics and epigenetics of glioblastoma: therapeutic challenges. Clin Cancer Investig J. 2018;7(2):43.
Uddin MS, Mamun AA, Alghamdi BS, Tewari D, Jeandet P, Sarwar MS, et al. Epigenetics of glioblastoma multiforme: from molecular mechanisms to therapeutic approaches. Semin Cancer Biol. 2022;83:100–120.
Jaenisch R, Bird A. Epigenetic regulation of gene expression: how the genome integrates intrinsic and environmental signals. Nat Genet. 2003;33(3):245–254.
Li Y. Modern epigenetics methods in biological research. Methods. 2021;187:104–113.
Dupont C, Armant DR, Brenner CA. Epigenetics: definition, mechanisms and clinical perspective. Semin Reprod Med. 2009;27(5):351–357.
Sharma S, Kelly TK, Jones PA. Epigenetics in cancer. Carcinogenesis. 2010;31(1):27–36.
Tahiliani M, Koh KP, Shen Y, Pastor WA, Bandukwala H, Brudno Y, et al. Conversion of 5‐methylcytosine to 5‐hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science. 2009;324(5929):930–935.
Iyer LM, Tahiliani M, Rao A, Aravind L. Prediction of novel families of enzymes involved in oxidative and other complex modifications of bases in nucleic acids. Cell Cycle. 2009;8(11):1698–1710.
Gardiner‐Garden M, Frommer M. CpG islands in vertebrate genomes. J Mol Biol. 1987;196(2):261–282.
Hannenhalli S, Levy S. Promoter prediction in the human genome. Bioinformatics. 2001;17(Suppl 1):S90–S96.
Larsen F, Gundersen G, Lopez R, Prydz H. CpG islands as gene markers in the human genome. Genomics. 1992;13(4):1095–1107.
Noguera‐Castells A, García‐Prieto CA, Álvarez‐Errico D, Esteller M. Validation of the new EPIC DNA methylation microarray (900K EPIC v2) for high‐throughput profiling of the human DNA methylome. Epigenetics. 2023;18(1):2185742.
Beck D, Ben Maamar M, Skinner MK. Genome‐wide CpG density and DNA methylation analysis method (MeDIP, RRBS, and WGBS) comparisons. Epigenetics. 2022;17(5):518–530.
Costello JF, Frühwald MC, Smiraglia DJ, Rush LJ, Robertson GP, Gao X, et al. Aberrant CpG‐Island methylation has non‐random and tumour‐type‐specific patterns. Nat Genet. 2000;24(2):132–138.
Graff JR, Herman JG, Lapidus RG, Chopra H, Xu R, Jarrard DF, et al. E‐cadherin expression is silenced by DNA hypermethylation in human breast and prostate carcinomas. Cancer Res. 1995;55(22):5195–5199.
Melki JR, Vincent PC, Clark SJ. Concurrent DNA hypermethylation of multiple genes in acute myeloid leukemia. Cancer Res. 1999;59(15):3730–3740.
Nguyen C, Liang G, Nguyen TT, Tsao‐Wei D, Groshen S, Lubbert M, et al. Susceptibility of nonpromoter CpG islands to de novo methylation in normal and neoplastic cells. J Natl Cancer Inst. 2001;93(19):1465–1472.
Issa JP. CpG Island methylator phenotype in cancer. Nat Rev Cancer. 2004;4(12):988–993.
Pfeifer GP, Rauch TA. DNA methylation patterns in lung carcinomas. Semin Cancer Biol. 2009;19(3):181–187.
Butler M, Pongor L, Su YT, Xi L, Raffeld M, Quezado M, et al. MGMT status as a clinical biomarker in glioblastoma. Trends Cancer. 2020;6(5):380–391.
Chai RC, Chang YZ, Wang QW, Zhang KN, Li JJ, Huang H, et al. A novel DNA methylation‐based signature can predict the responses of MGMT promoter Unmethylated glioblastomas to Temozolomide. Front Genet. 2019;10:910.
Pandith AA, Qasim I, Zahoor W, Shah P, Bhat AR, Sanadhya D, et al. Concordant association validates MGMT methylation and protein expression as favorable prognostic factors in glioma patients on alkylating chemotherapy (Temozolomide). Sci Rep. 2018;8(1):6704.
Jesionek‐Kupnicka D, Szybka M, Malachowska B, Fendler W, Potemski P, Piaskowski S, et al. TP53 promoter methylation in primary glioblastoma: relationship with TP53 mRNA and protein expression and mutation status. DNA Cell Biol. 2014;33(4):217–226.
Felsberg J, Yan PS, Huang THM, Milde U, Schramm J, Wiestler OD, et al. DNA methylation and allelic losses on chromosome arm 14q in oligodendroglial tumours. Neuropathol Appl Neurobiol. 2006;32(5):517–524.
Nakamura M, Yonekawa Y, Kleihues P, Ohgaki H. Promoter hypermethylation of the RB1 gene in glioblastomas. Lab Invest. 2001;81(1):77–82.
Costello JF, Berger MS, Huang HS, Cavenee WK. Silencing of p16/CDKN2 expression in human gliomas by methylation and chromatin condensation. Cancer Res. 1996;56(10):2405–2410.
Baeza N, Weller M, Yonekawa Y, Kleihues P, Ohgaki H. PTEN methylation and expression in glioblastomas. Acta Neuropathol. 2003;106(5):479–485.
Amatya VJ, Naumann U, Weller M, Ohgaki H. TP53 promoter methylation in human gliomas. Acta Neuropathol. 2005;110(2):178–184.
Noushmehr H, Weisenberger DJ, Diefes K, Phillips HS, Pujara K, Berman BP, et al. Identification of a CpG Island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell. 2010;17(5):510–522.
Sturm D, Witt H, Hovestadt V, Khuong‐Quang DA, Jones DTW, Konermann C, et al. Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. Cancer Cell. 2012;22(4):425–437.
Ceccarelli M, Barthel FP, Malta TM, Sabedot TS, Salama SR, Murray BA, et al. Molecular profiling reveals biologically discrete subsets and pathways of progression in diffuse glioma. Cell. 2016;164(3):550–563.
Verburg N, Barthel FP, Anderson KJ, Johnson KC, Koopman T, Yaqub MM, et al. Spatial concordance of DNA methylation classification in diffuse glioma. Neuro Oncol. 2021;23(12):2054–2065.
de Souza CF, Sabedot TS, Malta TM, Stetson L, Morozova O, Sokolov A, et al. A distinct DNA methylation shift in a subset of glioma CpG Island Methylator phenotypes during tumor recurrence. Cell Rep. 2018;23(2):637–651.
Wu Y, Fletcher M, Gu Z, Wang Q, Costa B, Bertoni A, et al. Glioblastoma epigenome profiling identifies SOX10 as a master regulator of molecular tumour subtype. Nat Commun. 2020;11(1):6434.
Drexler R, Schüller U, Eckhardt A, Filipski K, Hartung TI, Harter PN, et al. DNA methylation subclasses predict the benefit from gross total tumor resection in IDH‐wildtype glioblastoma patients. Neuro Oncol. 2023;25(2):315–325.
Varn FS, Johnson KC, Martinek J, Huse JT, Nasrallah MLP, Wesseling P, et al. Glioma progression is shaped by genetic evolution and microenvironment interactions. Cell. 2022;185(12):2184–2199.e16.
Capper D, Jones DTW, Sill M, Hovestadt V, Schrimpf D, Sturm D, et al. DNA methylation‐based classification of central nervous system tumours. Nature. 2018;555(7697):469–474.
Capper D, Stichel D, Sahm F, Jones DTW, Schrimpf D, Sill M, et al. Practical implementation of DNA methylation and copy‐number‐based CNS tumor diagnostics: the Heidelberg experience. Acta Neuropathol. 2018;136(2):181–210.
Karimi S, Zuccato JA, Mamatjan Y, Mansouri S, Suppiah S, Nassiri F, et al. The central nervous system tumor methylation classifier changes neuro‐oncology practice for challenging brain tumor diagnoses and directly impacts patient care. Clin Epigenetics. 2019;11(1):185.
Wenger A, Carén H. Methylation profiling in diffuse gliomas: diagnostic value and considerations. Cancers (Basel). 2022;14(22):5679.
Singh J, Sahu S, Mohan T, Mahajan S, Sharma MC, Sarkar C, et al. Current status of DNA methylation profiling in neuro‐oncology as a diagnostic support tool: a review. Neurooncol Pract. 2023;10:518–526.
Klughammer J, Kiesel B, Roetzer T, Fortelny N, Nemc A, Nenning KH, et al. The DNA methylation landscape of glioblastoma disease progression shows extensive heterogeneity in time and space. Nat Med. 2018;24(10):1611–1624.
Dejaegher J, Solie L, Hunin Z, Sciot R, Capper D, Siewert C, et al. DNA methylation based glioblastoma subclassification is related to tumoral T‐cell infiltration and patient survival. Neuro Oncol. 2021;23(2):240–250.
Yang I, Tihan T, Han SJ, Wrensch MR, Wiencke J, Sughrue ME, et al. CD8+ T‐cell infiltrate in newly diagnosed glioblastoma is associated with long‐term survival. J Clin Neurosci. 2010;17(11):1381–1385.
Kmiecik J, Poli A, Brons NHC, Waha A, Eide GE, Enger PØ, et al. Elevated CD3+ and CD8+ tumor‐infiltrating immune cells correlate with prolonged survival in glioblastoma patients despite integrated immunosuppressive mechanisms in the tumor microenvironment and at the systemic level. J Neuroimmunol. 2013;264(1–2):71–83.
Lohr J, Ratliff T, Huppertz A, Ge Y, Dictus C, Ahmadi R, et al. Effector T‐cell infiltration positively impacts survival of glioblastoma patients and is impaired by tumor‐derived TGF‐β. Clin Cancer Res. 2011;17(13):4296–4308.
Fornara O, Odeberg J, Solberg NW, Tammik C, Skarman P, Peredo I, et al. Poor survival in glioblastoma patients is associated with early signs of immunosenescence in the CD4 T‐cell compartment after surgery. Onco Targets Ther. 2015;4(9):e1036211.
Rutledge WC, Kong J, Gao J, Gutman DA, Cooper LAD, Appin C, et al. Tumor‐infiltrating lymphocytes in glioblastoma are associated with specific genomic alterations and related to transcriptional class. Clin Cancer Res. 2013;19(18):4951–4960.
Ricklefs FL, Drexler R, Wollmann K, Eckhardt A, Heiland DH, Sauvigny T, et al. DNA methylation subclass receptor tyrosine kinase II (RTK II) is predictive for seizure development in glioblastoma patients. Neuro Oncol. 2022;24(11):1886–1897.
Allfrey VG, Faulkner R, Mirsky A. Acetylation and methylation of histones and their possible role in the regulation of RNA synthesis. Proc Natl Acad Sci USA. 1964;51(5):786–794.
Yun M, Wu J, Workman JL, Li B. Readers of histone modifications. Cell Res. 2011;21(4):564–578.
Black JC, Van Rechem C, Whetstine JR. Histone lysine methylation dynamics: establishment, regulation, and biological impact. Mol Cell. 2012;48(4):491–507.
Annunziato AT, Hansen JC. Role of histone acetylation in the assembly and modulation of chromatin structures. Gene Expr. 2000;9(1–2):37–61.
Tessarz P, Kouzarides T. Histone core modifications regulating nucleosome structure and dynamics. Nat Rev Mol Cell Biol. 2014;15(11):703–708.
Danko CG, Hyland SL, Core LJ, Martins AL, Waters CT, Lee HW, et al. Identification of active transcriptional regulatory elements from GRO‐seq data. Nat Methods. 2015;12(5):433–438.
Whyte WA, Orlando DA, Hnisz D, Abraham BJ, Lin CY, Kagey MH, et al. Master transcription factors and mediator establish super‐enhancers at key cell identity genes. Cell. 2013;153(2):307–319.
Ma S, Zhang Y. Profiling chromatin regulatory landscape: insights into the development of ChIP‐seq and ATAC‐seq. Mol Biomed. 2020;1(1):9.
Robertson G, Hirst M, Bainbridge M, Bilenky M, Zhao Y, Zeng T, et al. Genome‐wide profiles of STAT1 DNA association using chromatin immunoprecipitation and massively parallel sequencing. Nat Methods. 2007;4(8):651–657.
Mardis ER. ChIP‐seq: welcome to the new frontier. Nat Methods. 2007;4(8):613–614.
Skene PJ, Henikoff S. An efficient targeted nuclease strategy for high‐resolution mapping of DNA binding sites. Elife. 2017;6:e21856.
Kaya‐Okur HS, Wu SJ, Codomo CA, Pledger ES, Bryson TD, Henikoff JG, et al. CUT&Tag for efficient epigenomic profiling of small samples and single cells. Nat Commun. 2019;10(1):1930.
Kaya‐Okur HS, Janssens DH, Henikoff JG, Ahmad K, Henikoff S. Efficient low‐cost chromatin profiling with CUT&Tag. Nat Protoc. 2020;15(10):3264–3283.
Buenrostro JD, Wu B, Chang HY, Greenleaf WJ. ATAC‐seq: a method for assaying chromatin accessibility genome‐wide. Curr Protoc Mol Biol. 2015;109:21.29.1–21.29.9.
Grandi FC, Modi H, Kampman L, Corces MR. Chromatin accessibility profiling by ATAC‐seq. Nat Protoc. 2022;17(6):1518–1552.
Fontebasso AM, Liu XY, Sturm D, Jabado N. Chromatin remodeling defects in pediatric and Young adult glioblastoma: a tale of a variant histone 3 tail. Brain Pathol. 2013;23(2):210–216.
Maleszewska M, Kaminska B. Is glioblastoma an epigenetic malignancy? Cancer. 2013;5(3):1120–1139.
Califano A, Alvarez MJ. The recurrent architecture of tumour initiation, progression and drug sensitivity. Nat Rev Cancer. 2017;17(2):116–130.
Alvarez MJ, Subramaniam PS, Tang LH, Grunn A, Aburi M, Rieckhof G, et al. A precision oncology approach to the pharmacological targeting of mechanistic dependencies in neuroendocrine tumors. Nat Genet. 2018;50(7):979–989.
Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge‐based approach for interpreting genome‐wide expression profiles. Proc Natl Acad Sci USA. 2005;102(43):15545–15550.
Mack SC, Singh I, Wang X, Hirsch R, Wu Q, Villagomez R, et al. Chromatin landscapes reveal developmentally encoded transcriptional states that define human glioblastoma. J Exp Med. 2019;216(5):1071–1090.
Neftel C, Laffy J, Filbin MG, Hara T, Shore ME, Rahme GJ, et al. An integrative model of cellular states, plasticity, and genetics for glioblastoma. Cell. 2019;178(4):835–849.e21.
Lu X, Maturi NP, Jarvius M, Yildirim I, Dang Y, Zhao L, et al. Cell‐lineage controlled epigenetic regulation in glioblastoma stem cells determines functionally distinct subgroups and predicts patient survival. Nat Commun. 2022;13(1):2236.
Guilhamon P, Chesnelong C, Kushida MM, Nikolic A, Singhal D, MacLeod G, et al. Single‐cell chromatin accessibility profiling of glioblastoma identifies an invasive cancer stem cell population associated with lower survival. Elife. 2021;10:e64090.
Reimand J, Arak T, Adler P, Kolberg L, Reisberg S, Peterson H, et al. G:profiler‐a web server for functional interpretation of gene lists (2016 update). Nucleic Acids Res. 2016;44(W1):W83–W89.
Somasundaram K, Reddy SP, Vinnakota K, Britto R, Subbarayan M, Nambiar S, et al. Upregulation of ASCL1 and inhibition of notch signaling pathway characterize progressive astrocytoma. Oncogene. 2005;24(47):7073–7083.
Ligon KL, Alberta JA, Kho AT, Weiss J, Kwaan MR, Nutt CL, et al. The oligodendroglial lineage marker OLIG2 is universally expressed in diffuse gliomas. J Neuropathol Exp Neurol. 2004;63(5):499–509.
Eferl R, Wagner EF. AP‐1: a double‐edged sword in tumorigenesis. Nat Rev Cancer. 2003;3(11):859–868.
Gao Y, Gan K, Liu K, Xu B, Chen M. SP1 expression and the Clinicopathological features of tumors: a meta‐analysis and bioinformatics analysis. Pathol Oncol Res. 2021;27:581998.
Chu T, Rice EJ, Booth GT, Salamanca HH, Wang Z, Core LJ, et al. Chromatin run‐on and sequencing maps the transcriptional regulatory landscape of glioblastoma multiforme. Nat Genet. 2018;50(11):1553–1564.
Johnson JE. Chapter 14 – bHLH factors in neurogenesis and neuronal subtype specification. In: Rubenstein J, Rakic P, editors. Patterning and cell type specification in the developing CNS and PNS. 2nd ed. Academic Press; 2020. p. 311–332.
Bhat KPL, Balasubramaniyan V, Vaillant B, Ezhilarasan R, Hummelink K, Hollingsworth F, et al. Mesenchymal differentiation mediated by NF‐κB promotes radiation resistance in glioblastoma. Cancer Cell. 2013;24(3):331–346.
Wang Z, Zhang H, Xu S, Liu Z, Cheng Q. The adaptive transition of glioblastoma stem cells and its implications on treatments. Signal Transduct Target Ther. 2021;6(1):124.
Xu L, Chen Y, Huang Y, Sandanaraj E, Yu JS, Lin RYT, et al. Topography of transcriptionally active chromatin in glioblastoma. Sci Adv. 2021;7(18):eabd4676.
Pine AR, Cirigliano SM, Singhania R, Nicholson J, da Silva B, Leslie CS, et al. Microenvironment‐driven dynamic chromatin changes in glioblastoma recapitulate early neural development at single‐cell resolution. Cancer Res. 2023;83:1581–1595.
Sati I, Parhar I. MicroRNAs regulate cell cycle and cell death pathways in glioblastoma. Int J Mol Sci. 2021;22(24):13550.
Banelli B, Forlani A, Allemanni G, Morabito A, Pistillo MP, Romani M. MicroRNA in glioblastoma: an overview. Int J Genomics. 2017;2017:7639084.
Tsang JS, Ebert MS, van Oudenaarden A. Genome‐wide dissection of microRNA functions and cotargeting networks using gene set signatures. Mol Cell. 2010;38(1):140–153.
González‐Gómez P, Sánchez P, Mira H. MicroRNAs as regulators of neural stem cell‐related pathways in glioblastoma multiforme. Mol Neurobiol. 2011;44(3):235–249.
Lu J, Getz G, Miska EA, Alvarez‐Saavedra E, Lamb J, Peck D, et al. MicroRNA expression profiles classify human cancers. Nature. 2005;435(7043):834–838.
Silber J, Lim DA, Petritsch C, Persson AI, Maunakea AK, Yu M, et al. miR‐124 and miR‐137 inhibit proliferation of glioblastoma multiforme cells and induce differentiation of brain tumor stem cells. BMC Med. 2008;6:14.
Rosenfeld N, Aharonov R, Meiri E, Rosenwald S, Spector Y, Zepeniuk M, et al. MicroRNAs accurately identify cancer tissue origin. Nat Biotechnol. 2008;26(4):462–469.
Kim TM, Huang W, Park R, Park PJ, Johnson MD. A developmental taxonomy of glioblastoma defined and maintained by MicroRNAs. Cancer Res. 2011;71(9):3387–3399.
Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell. 2010;17(1):98–110.
Sathyan P, Zinn PO, Marisetty AL, Liu B, Kamal MM, Singh SK, et al. Mir‐21‐Sox2 Axis delineates glioblastoma subtypes with prognostic impact. J Neurosci. 2015;35(45):15097–15112.
Schulte A, Günther HS, Phillips HS, Kemming D, Martens T, Kharbanda S, et al. A distinct subset of glioma cell lines with stem cell‐like properties reflects the transcriptional phenotype of glioblastomas and overexpresses CXCR4 as therapeutic target. Glia. 2011;59(4):590–602.
Marziali G, Buccarelli M, Giuliani A, Ilari R, Grande S, Palma A, et al. A three‐microRNA signature identifies two subtypes of glioblastoma patients with different clinical outcomes. Mol Oncol. 2017;11(9):1115–1129.
Rooj AK, Ricklefs F, Mineo M, Nakano I, Chiocca EA, Bronisz A, et al. MicroRNA‐mediated dynamic bidirectional shift between the subclasses of glioblastoma stem‐like cells. Cell Rep. 2017;19(10):2026–2032.
Schneider B, William D, Lamp N, Zimpfer A, Henker C, Classen CF, et al. The miR‐183/96/182 cluster is upregulated in glioblastoma carrying EGFR amplification. Mol Cell Biochem. 2022;477(9):2297–2307.
Nayak S, Aich M, Kumar A, Sengupta S, Bajad P, Dhapola P, et al. Novel internal regulators and candidate miRNAs within miR‐379/miR‐656 miRNA cluster can alter cellular phenotype of human glioblastoma. Sci Rep. 2018;8(1):7673.
Zhang W, Zhang J, Hoadley K, Kushwaha D, Ramakrishnan V, Li S, et al. miR‐181d: a predictive glioblastoma biomarker that downregulates MGMT expression. Neuro Oncol. 2012;14(6):712–719.
Rezaei O, Honarmand K, Nateghinia S, Taheri M, Ghafouri‐Fard S. miRNA signature in glioblastoma: potential biomarkers and therapeutic targets. Exp Mol Pathol. 2020;117:104550.
Kouri FM, Ritner C, Stegh AH. miRNA‐182 and the regulation of the glioblastoma phenotype ‐ toward miRNA‐based precision therapeutics. Cell Cycle. 2015;14(24):3794–3800.
Yuan Y, Zhang H, Liu X, Lu Z, Li G, Lu M, et al. MicroRNA signatures predict prognosis of patients with glioblastoma multiforme through the cancer genome atlas. Oncotarget. 2017;8(35):58386–58393.
Unger K, Fleischmann DF, Ruf V, Felsberg J, Piehlmaier D, Samaga D, et al. Improved risk stratification in younger IDH wild‐type glioblastoma patients by combining a 4‐miRNA signature with MGMT promoter methylation status. Neurooncol Adv. 2020;2(1):vdaa137.
Bafiti V, Ouzounis S, Chalikiopoulou C, Grigorakou E, Grypari IM, Gregoriou G, et al. A 3‐miRNA signature enables risk stratification in glioblastoma Multiforme patients with different clinical outcomes. Curr Oncol. 2022;29(6):4315–4331.
Tang Y, Wang J, Lian Y, Fan C, Zhang P, Wu Y, et al. Linking long non‐coding RNAs and SWI/SNF complexes to chromatin remodeling in cancer. Mol Cancer. 2017;16(1):42.
Wahlestedt C. Targeting long non‐coding RNA to therapeutically upregulate gene expression. Nat Rev Drug Discov. 2013;12(6):433–446.
Schmitt AM, Chang HY. Long noncoding RNAs in cancer pathways. Cancer Cell. 2016;29(4):452–463.
Quinn JJ, Chang HY. Unique features of long non‐coding RNA biogenesis and function. Nat Rev Genet. 2016;17(1):47–62.
He RZ, Luo DX, Mo YY. Emerging roles of lncRNAs in the post‐transcriptional regulation in cancer. Genes Dis. 2019;6(1):6–15.
Slack FJ, Chinnaiyan AM. The role of non‐coding RNAs in oncology. Cell. 2019;179(5):1033–1055.
Zhang X, Wang W, Zhu W, Dong J, Cheng Y, Yin Z, et al. Mechanisms and functions of Long non‐coding RNAs at multiple regulatory levels. Int J Mol Sci. 2019;20(22):5573.
Guttman M, Amit I, Garber M, French C, Lin MF, Feldser D, et al. Chromatin signature reveals over a thousand highly conserved large non‐coding RNAs in mammals. Nature. 2009;458(7235):223–227.
Guenther MG, Levine SS, Boyer LA, Jaenisch R, Young RA. A chromatin landmark and transcription initiation at most promoters in human cells. Cell. 2007;130(1):77–88.
Mercer TR, Mattick JS. Structure and function of long noncoding RNAs in epigenetic regulation. Nat Struct Mol Biol. 2013;20(3):300–307.
Spitale RC, Tsai MC, Chang HY. RNA templating the epigenome: long noncoding RNAs as molecular scaffolds. Epigenetics. 2011;6(5):539–543.
Tay Y, Rinn J, Pandolfi PP. The multilayered complexity of ceRNA crosstalk and competition. Nature. 2014;505(7483):344–352.
Arnold PR, Wells AD, Li XC. Diversity and emerging roles of enhancer RNA in regulation of gene expression and cell fate. Front Cell Dev Biol. 2019;7:377.
Katsushima K, Jallo G, Eberhart CG, Perera RJ. Long non‐coding RNAs in brain tumors. NAR Cancer. 2021;3(1):zcaa041.
Reon BJ, Anaya J, Zhang Y, Mandell J, Purow B, Abounader R, et al. Expression of lncRNAs in low‐grade gliomas and glioblastoma Multiforme: an in Silico analysis. PLoS Med. 2016;13(12):e1002192.
Hu W, Wang T, Yang Y, Zheng S. Tumor heterogeneity uncovered by dynamic expression of long noncoding RNA at single‐cell resolution. Cancer Genet. 2015;208(12):581–586.
Li Q, Yu Q, Ji J, Wang P, Li D. Comparison and analysis of lncRNA‐mediated ceRNA regulation in different molecular subtypes of glioblastoma. Mol Omics. 2019;15(6):406–419.
Yu W, Ma Y, Hou W, Wang F, Cheng W, Qiu F, et al. Identification of immune‐related lncRNA prognostic signature and molecular subtypes for glioblastoma. Front Immunol. 2021;12:706936.
Dikshit B, Irshad K, Madan E, Aggarwal N, Sarkar C, Chandra PS, et al. FAT1 acts as an upstream regulator of oncogenic and inflammatory pathways, via PDCD4, in glioma cells. Oncogene. 2013;32(33):3798–3808.
Blasi F, Carmeliet P. uPAR: a versatile signalling orchestrator. Nat Rev Mol Cell Biol. 2002;3(12):932–943.
Wood MD, Reis GF, Reuss DE, Phillips JJ. Protein analysis of glioblastoma primary and Posttreatment pairs suggests a mesenchymal shift at recurrence. J Neuropathol Exp Neurol. 2016;75(10):925–935.
Barnes JM, Kaushik S, Bainer RO, Sa JK, Woods EC, Kai FB, et al. A tension‐mediated glycocalyx‐integrin feedback loop promotes mesenchymal‐like glioblastoma. Nat Cell Biol. 2018;20(10):1203–1214.
Hara T, Chanoch‐Myers R, Mathewson ND, Myskiw C, Atta L, Bussema L, et al. Interactions between cancer cells and immune cells drive transitions to mesenchymal‐like states in glioblastoma. Cancer Cell. 2021;39(6):779–792.e11.
Wu W, Yu T, Wu Y, Tian W, Zhang J, Wang Y. The miR155HG/miR‐185/ANXA2 loop contributes to glioblastoma growth and progression. J Exp Clin Cancer Res. 2019;38(1):133.
Jiang X, Chen D. LncRNA FAM181A‐AS1 promotes gliomagenesis by sponging miR‐129‐5p and upregulating ZRANB2. Aging (Albany NY). 2020;12(20):20069–20084.
Huang K, Yue X, Zheng Y, Zhang Z, Cheng M, Li L, et al. Development and validation of an mesenchymal‐related Long non‐coding RNA prognostic model in glioma. Front Oncol. 2021;11:726745.
Liang Q, Guan G, Li X, Wei C, Wu J, Cheng P, et al. Profiling pro‐neural to mesenchymal transition identifies a lncRNA signature in glioma. J Transl Med. 2020;18(1):378.
Meng Q, Zhang Y, Li G, Li Y, Xie H, Chen X. New insights for precision treatment of glioblastoma from analysis of single‐cell lncRNA expression. J Cancer Res Clin Oncol. 2021;147(7):1881–1895.
Lee JH, Lee JE, Kahng JY, Kim SH, Park JS, Yoon SJ, et al. Human glioblastoma arises from subventricular zone cells with low‐level driver mutations. Nature. 2018;560(7717):243–247.
Duan S, Yuan G, Liu X, Ren R, Li J, Zhang W, et al. PTEN deficiency reprogrammes human neural stem cells towards a glioblastoma stem cell‐like phenotype. Nat Commun. 2015;6:10068.
Zheng H, Ying H, Yan H, Kimmelman AC, Hiller DJ, Chen AJ, et al. p53 and Pten control neural and glioma stem/progenitor cell renewal and differentiation. Nature. 2008;455(7216):1129–1133.
Alcantara Llaguno S, Chen J, Kwon CH, Jackson EL, Li Y, Burns DK, et al. Malignant astrocytomas originate from neural stem/progenitor cells in a somatic tumor suppressor mouse model. Cancer Cell. 2009;15(1):45–56.
Alcantara Llaguno SR, Wang Z, Sun D, Chen J, Xu J, Kim E, et al. Adult lineage‐restricted CNS progenitors specify distinct glioblastoma subtypes. Cancer Cell. 2015;28(4):429–440.
Alcantara Llaguno S, Sun D, Pedraza AM, Vera E, Wang Z, Burns DK, et al. Cell‐of‐origin susceptibility to glioblastoma formation declines with neural lineage restriction. Nat Neurosci. 2019;22(4):545–555.
Boot J, Rosser G, Kancheva D, Vinel C, Lim YM, Pomella N, et al. Global hypo‐methylation in a proportion of glioblastoma enriched for an astrocytic signature is associated with increased invasion and altered immune landscape. Elife. 2022;11:e77335.
Jacob F, Salinas RD, Zhang DY, Nguyen PTT, Schnoll JG, Wong SZH, et al. A patient‐derived glioblastoma organoid model and biobank recapitulates inter and intratumoral heterogeneity. Cell. 2020;180(1):188–204.e22.
Linkous A, Balamatsias D, Snuderl M, Edwards L, Miyaguchi K, Milner T, et al. Modeling patient‐derived glioblastoma with cerebral organoids. Cell Rep. 2019;26(12):3203–3211.e5.
Pine AR, Cirigliano SM, Nicholson JG, Hu Y, Linkous A, Miyaguchi K, et al. Tumor microenvironment is critical for the maintenance of cellular states found in primary glioblastomas. Cancer Discov. 2020;10(7):964–979.
Vaubel RA, Tian S, Remonde D, Schroeder MA, Mladek AC, Kitange GJ, et al. Genomic and phenotypic characterization of a broad panel of patient‐derived xenografts reflects the diversity of glioblastoma. Clin Cancer Res. 2020;26(5):1094–1104.
Zhou D, Alver BM, Li S, Hlady RA, Thompson JJ, Schroeder MA, et al. Distinctive epigenomes characterize glioma stem cells and their response to differentiation cues. Genome Biol. 2018;19(1):43.
Vinel C, Rosser G, Guglielmi L, Constantinou M, Pomella N, Zhang X, et al. Comparative epigenetic analysis of tumour initiating cells and syngeneic EPSC‐derived neural stem cells in glioblastoma. Nat Commun. 2021;12(1):6130.
Badodi S, Marino S. Epigenetic mechanisms in paediatric brain tumours: regulators lose control. Biochem Soc Trans. 2022;50(1):167–185.
Suter RK, Rodriguez‐Blanco J, Ayad NG. Epigenetic pathways and plasticity in brain tumors. Neurobiol Dis. 2020;145:105060.
Jovčevska I. Next generation sequencing and machine learning technologies are painting the epigenetic portrait of glioblastoma. Front Oncol. 2020;10:798.
Cheng F, Lu W, Liu C, Fang J, Hou Y, Handy DE, et al. A genome‐wide positioning systems network algorithm for in silico drug repurposing. Nat Commun. 2019;10(1):3476.
Cannon M, Stevenson J, Stahl K, Basu R, Coffman A, Kiwala S, et al. DGIdb 5.0: rebuilding the drug‐gene interaction database for precision medicine and drug discovery platforms. Nucleic Acids Res. 2024;52(D1):D1227–D1235.